A proposed Medicare payment change would make the employment relationship behind remote monitoring consequential: CMS proposes paying for the relevant monitoring services when clinical staff are employed by the practice, rather than supplied by contractors. It is a proposal for 2027, not a present ban on connected blood-pressure cuffs or other home devices. CMS proposed-rule fact sheet
The debate concerns how a care service is staffed and paid for. A device can keep transmitting while the organisation responsible for reviewing its data faces a different financial arrangement.
What CMS actually proposes
In its Remote Monitoring section, CMS addresses remote physiologic monitoring, or RPM, and remote therapeutic monitoring, or RTM. Alongside the proposed employee-versus-contractor payment condition, the agency proposes an initiating visit associated with starting monitoring and an established-patient requirement for RTM.
CMS also proposes changes to valuation and seeks comments on a possible bundled coding approach. Those are separate elements of the proposal, rather than a single statement that every form of remote monitoring will cease. Remote Monitoring policy summary
The employment condition should not be confused with a requirement that every staff member physically sits in the practice building. The cited CMS summary distinguishes employment from contracting; it does not define the proposal as a blanket prohibition on staff working remotely. This article explains the proposal’s structure, not a billing or compliance determination for an individual practice.
Why the outside team matters to rural services
KFF Health News reported on 26 October that some rural practices depend on external companies for devices, nursing contact and monitoring capacity. Its reporting includes clinicians concerned that they lack the staff and resources to bring that work in-house. KFF’s reporting on access concerns
That is a practical distinction between buying equipment and running a service. A monitoring arrangement can include onboarding, incoming measurements, patient calls and communication with the usual care team. Changing who can be paid for that work can matter even when the cuff itself is unchanged.
The reporting also describes disagreement among stakeholders, including organisations supporting stronger restrictions and others forecasting reduced access. These are reported positions and forecasts, not observed effects of an already implemented final policy. Potential responses by other insurers are similarly not evidence that those insurers have adopted the same rule.
The oversight concern is real, but separate
An HHS Office of Inspector General review found that about 43% of Medicare enrollees receiving remote monitoring did not receive all three components described in its analysis. The review also identified missing information needed for oversight, including who ordered monitoring. OIG’s 2024 review
Those findings raise questions about service delivery and billing. They do not mean that 43% of patients received no benefit, or prove that every contractor-led programme is inappropriate. The denominator concerns enrollees in the reviewed monitoring services, not everyone enrolled in Medicare.
OIG recommended safeguards, better ordering-provider information, methods to identify the data being monitored, provider education and monitoring of billing companies. These oversight objectives are worth distinguishing from the particular policy mechanism CMS now proposes.
Three questions that should remain separate
| Question | What answers it |
|---|---|
| Is the device producing and transmitting usable information? | Evidence about that device and data flow |
| Who reviews the information and acts on it? | The programme’s clinical responsibilities and care model |
| Which staffing arrangement can receive payment? | The applicable payer’s final policy and effective dates |
Our digital blood-pressure care analysis addresses the second question through evidence about different care models. A payment restriction does not establish device accuracy or clinical effectiveness, while a beneficial care model does not determine how Medicare will pay for it.
The next material check is the final 2027 policy and its implementation details. Until then, the accurate description is a contested proposal about payment and staffing, with rural-access concerns that require evaluation rather than a forecast presented as fact.